MidCap Financial
VC Fund
Bethesda, United States
MidCap Financial is a middle market-focused, specialty finance firm that provides senior debt solutions to companies across all industries. We provide a broad array of products intended to finance growth and manage working capital. As of January 2015, MidCap Financial has over $3 billion of commitments under management. Since our founding in2008, we have been working with management teams and sponsors to deliver thoughtful and cost effective debt solutions. Companies need a lender that understands their business and has the creativity and flexibility to provide financing solutions that are suited to their needs. At MidCap Financial, our years of experience, strong balance sheet, and flexibility make us the lender of choice for companies across all stages of growth and complexity. MidCap Financial is managed by Apollo Capital Management, L.P., a subsidiary of Apollo Global Management, LLC, pursuant to an investment management agreement. Apollo Global Management is one of the world's largest asset managers with over $160B of assets under management (as of January 2015), providing market leading industry expertise, market reach, and financing synergies.
- Total investments:
- 66
- Last investment:
- Lead investor:
- 68%
- Fund size:
- $12M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries MidCap Financial invests in
Stages MidCap Financial invests in
Countries MidCap Financial invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
David Moore
|
|||
Michael Cheng
|
|||
Michael Marziani
|
|||
|
Steve Curwin
|
|||
Investment Focus
Industry
- Health Care 30 (45%)
- Biotechnology 28 (42%)
- Medical Device 15 (23%)
- Medical 14 (21%)
- Manufacturing 12 (18%)
Stage
- Post-IPO Debt 31 (47%)
- Debt Financing 25 (38%)
- Series A 2 (3%)
- Series D 2 (3%)
- Funding Round 2 (3%)
Country
- United States 55 (83%)
- United Kingdom 3 (5%)
- Canada 2 (3%)
- Australia 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
David Moore
Chief Financial Officer & Co-Founder
|
Chief Financial Officer & Co-Founder | Total investments: 0 | Find email | |
|
Michael Cheng
Managing Director
|
Managing Director | Total investments: 1 | Find email | |
|
Michael Marziani
Managing Director & Team Leader - Technology
|
Managing Director & Team Leader - Technology | Total investments: 0 | Find email | |
|
Steve Curwin
Co-Founder & CEO
|
Co-Founder & CEO | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
RH Aero Systems
|
RH Aero Systems supplies aviation support equipment, OEM-certified tools, and maintenance solutions for aircraft operations. | Debt Financing / Jul 27, 2026 | |
Cerus
|
Cerus Corporation is a biomedical products company focused in the field of blood safety. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. In the United States, Cerus is seekingregulatory approval of the INTERCEPT Blood System for plasma and platelets. The INTERCEPT red blood cell system is in clinical development. | $80M / Post-IPO Debt / Jun 08, 2026 | |
Made By Gather
|
Made By Gather is a manufacturer and designer of small kitchen appliances and kitchenware for the modern consumer. The company was established in 2003 by Shae Hong. | Debt Financing / May 13, 2026 | |
Novavax
|
Novavax is a biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax recently initiated the development of NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19, with Phase 1 clinicaltrial results expected in July 2020. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both vaccine candidates incorporate Novavax’s proprietary saponin-based Matrix-M™ adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies.Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs. | $50M / Post-IPO Debt / Feb 26, 2026 | |
Tissue Regenix
|
Tissue Regenix commercializes innovative technologies in regenerative medicine. | $500K / Post-IPO Debt / Dec 01, 2025 | |
Overhaul
|
Overhaul is a supply chain integrity solutions company that allows shippers to connect disparate sources of data into a fully transparent platform designed for the logistics industry. Data that is transformed into critical insights that can instantly trigger corrective actions, impacting everything from temperature control to handling requirementsor package-level tracking, ensuring cargo arrives at its destination safely, undamaged, and on time.All active shipments, all corresponding data sources, all in real-time through a single unified view. | Debt Financing / Aug 20, 2025 | |
Evolv Technology
|
Evolv Technology provides touchless security screening systems that ensure safety without sacrificing the visitor experience.Evolv’s Mosaiq Platform provides a first-of-its-kind solution, integrating real-time video surveillance with extremely low false alarms, walkthrough firearm, and explosive detection, facial recognition, and securityanalytics. Based in Waltham, Massachusetts, and led by veterans of the physical screening industry including the TSA, FBI, CIA, Secret Service, and Homeland Security, Evolv is dedicated to helping government agencies and private businesses protect their soft targets and their hard assets. | $75M / Post-IPO Debt / Jul 30, 2025 | |
NeuroPace
|
NeuroPace designs develops, manufactures, and markets implantable devices for the treatment of neurological disorders. It offers a responsive Neurostimulator system (RNS) for the treatment of medically refractory partial epilepsy. The company's RNS system consists of implantable components, including RNS neurostimulator that delivers a shorttrain of electrical pulses to the brain, and depth leads and cortical strip leads; and external products, such as the programmer, a laptop computer with proprietary software that has a wand and telemetry interface enabling communication with an implanted RNS neurostimulator. NeuroPace was incorporated in 1997 and is based in Mountain View, California. | $75M / Post-IPO Debt / Jun 04, 2025 | |
Kashable
|
Kashable offers low-cost loans for any purpose. Eligible federal and company-sponsored employees can apply online in minutes and set up automatic repayment via structured payroll deductions.Kashable is an intelligent option for those looking to tackle expensive debt, cover unexpected expenses, or access an affordable financing option. We providean instant decision online with funds deposited directly to your bank account within 3 business days from approval. We are Socially Responsible Credit™ | $250M / Debt Financing / May 29, 2025 | |
Urgently
|
Urgently is a digital roadside assistance platform that features a roadside assistance industry to the benefit of global brands, roadside assistance professionals, and consumers. Its solution delivers the quickest, safest, and most innovative roadside assistance service, products and technology by combining location-based services, real-time data,AI, and machine-to-machine communication. | $20M / Post-IPO Debt / Feb 26, 2025 | |
| See all 66 investments → | |||
Co-Investors
Oxford Finance LLC
3 deals together
MidCap Financial Investment
2 deals together
The TCW Group
2 deals together
Adams Street Partners
1 deal together
Apollo
1 deal together
Benevolent Capital
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does MidCap Financial invest in?
MidCap Financial invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Post-IPO Debt and Debt Financing stage. Most of the 66 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact MidCap Financial?
Public channels for MidCap Financial include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at MidCap Financial?
The team at MidCap Financial includes David Moore (Chief Financial Officer & Co-Founder), Michael Cheng (Managing Director) and Michael Marziani (Managing Director & Team Leader - Technology). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
